A Nanovaccine for Eliciting Broadly Neutralizing Antibodies Against HIV-1
Award Notice Posted
- Solicitation number
- PHS-2020-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Neovaxsyn Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020C00014 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
NEOVAXSYN INC was awarded a single contract valued at $299,999 by the National Institute of Allergy and Infectious Diseases to advance development of its nanovaccine aimed at eliciting broadly neutralizing antibodies against HIV-1. The contract will support NEOVAXSYN's work to design a potential vaccine that could help induce antibodies capable of neutralizing diverse strains of HIV-1, with the goal of aiding both prevention and treatment of HIV/AIDS. The National Institute of Allergy and Infectious Diseases is part of the Department of Health and Human Services.
Notice text
Awarded contract 75N93020C00014 to NEOVAXSYN INC for 299999.00 on 2020-06-01.
Notice history
5 of 7 notices listed here. See the rest on GovTribe.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity